US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Prima Biomed

1.71

0.0000

Volume:- -

Turnover:- -

Market Cap:35.25M

PE:-0.81

High:1.71

Open:1.71

Low:1.71

Close:1.71

52wk High:3.26

52wk Low:1.40

Shares:20.62M

Float Shares:19.28M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.1000

ROE:--

ROA:--

PB:1.41

PE(LYR):- -

Loading ...

Overview Company News Filings

Company Profile

Company Name:

Prima Biomed

Exchange:

NASDAQ

Establishment Date:

- -

Employees:

- -

Office Location:

- -

Website:

http://www.primabiomed.com.au

Zip Code:

- -

Phone:

- -

Fax:

- -

Introduction:

Prima BioMed Ltd. engages in the research, development, and commercialization of medical biotechnology products in Australia. The company develops immunotherapeutic products for the treatment of various types of cancer. Its core technologies are based on the LAG-3 immune control mechanism, which plays a vital role in the regulation of the T cell immune response. The companys lead product candidate is IMP321, a recombinant protein, which is in Phase IIb clinical trials in metastatic breast cancer when used as a chemo-immunotherapy, as well as in Phase I clinical trials in metastatic melanoma. Its other products include IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company is also developing CVac, an autologous dendritic cell-based product through Phase II clinical trials for ovarian cancer patients in remission. Prima BioMed Ltd. has strategic partnership agreement with Wuxi Biologics Co. Ltd. for developing IMP321 and other LAG-3 related products. Prima BioMed Ltd. is based in Sydney, Australia.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/PBMD/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"PBMD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PBMD\",,,,,undefined,":{"symbol":"PBMD","market":"US","secType":"STK","nameCN":"Prima Biomed","latestPrice":1.71,"timestamp":1512162000000,"preClose":1.71,"halted":4,"volume":0,"delay":0,"changeRate":0,"floatShares":19281474,"shares":20616000,"eps":-2.1,"marketStatus":"Delisted","change":0,"latestTime":"12-01 16:00:00 EST","open":1.71,"high":1.71,"low":1.71,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.1,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1771837200000},"marketStatusCode":7,"adr":1,"adrRate":0,"exchange":"NASDAQ","adjPreClose":1.71,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PBMD\",,,,,undefined,":{"symbol":"PBMD","floatShares":19281474,"roa":"--","roe":"--","lyrEps":0,"shares":20616000,"dividePrice":0,"high":1.71,"amplitude":0,"preClose":1.71,"low":1.71,"week52Low":1.4,"pbRate":"1.41","week52High":3.26,"institutionHeld":0,"latestPrice":1.71,"eps":-2.1,"divideRate":0,"volume":0,"delay":0,"ttmEps":-2.1,"open":1.71},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PBMD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2016-09-05","symbol":"PBMD","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1473048000000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PBMD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PBMD\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.primabiomed.com.au","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.0113},{"period":"1month","weight":0.0059},{"period":"3month","weight":0.0461},{"period":"6month","weight":0.0684},{"period":"1year","weight":0.1295},{"period":"ytd","weight":0.011}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Prima BioMed Ltd. engages in the research, development, and commercialization of medical biotechnology products in Australia. The company develops immunotherapeutic products for the treatment of various types of cancer. Its core technologies are based on the LAG-3 immune control mechanism, which plays a vital role in the regulation of the T cell immune response. The companys lead product candidate is IMP321, a recombinant protein, which is in Phase IIb clinical trials in metastatic breast cancer when used as a chemo-immunotherapy, as well as in Phase I clinical trials in metastatic melanoma. Its other products include IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company is also developing CVac, an autologous dendritic cell-based product through Phase II clinical trials for ovarian cancer patients in remission. Prima BioMed Ltd. has strategic partnership agreement with Wuxi Biologics Co. Ltd. for developing IMP321 and other LAG-3 related products. Prima BioMed Ltd. is based in Sydney, Australia.","exchange":"NASDAQ","name":"Prima Biomed","nameEN":"Prima Biomed"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"PBMD\",market:\"US\",,,undefined,":null}}